T1	Participants 76 114	patients with hematologic malignancies
T2	Participants 325 528	Seventy immunocompromised febrile patients with hematologic malignancies were randomly assigned to either a vancomycin therapeutic drug monitoring group (TDM group; n = 37) or to a control group (n = 33)
